Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRTA Stock Forecast 2026-2027
$10.90
Current Price
$586.78M
Market Cap
Buy 3
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PRTA Price Targets
+230.3%
To High Target of $36.00
+74.3%
To Median Target of $19.00
-26.6%
To Low Target of $8.00
PRTA Price Momentum
+5.7%
1 Week Change
+24.6%
1 Month Change
+18.5%
1 Year Change
+14.1%
Year-to-Date Change
-6.8%
From 52W High of $11.69
+152.3%
From 52W Low of $4.32
📊 TOP ANALYST CALLS
Did PRTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prothena is one of their latest high-conviction picks.
Latest PRTA Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, PRTA has a neutral consensus with a median price target of $19.00 (ranging from $8.00 to $36.00). The overall analyst rating is Buy (7.0/10). Currently trading at $10.90, the median forecast implies a 74.3% upside. This outlook is supported by 3 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 230.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRTA Analyst Ratings
3
Buy
2
Hold
1
Sell
PRTA Price Target Range
Low
$8.00
Average
$19.00
High
$36.00
Current: $10.90
Latest PRTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2026 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $12.00 |
| Dec 1, 2025 | Citizens | Jason Butler | Market Outperform | Maintains | $19.00 |
| Nov 7, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $30.00 |
| Nov 7, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $11.00 |
| Oct 28, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $36.00 |
| Oct 7, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $20.00 |
| Sep 2, 2025 | JMP Securities | Jason Butler | Market Outperform | Maintains | $11.00 |
| Aug 28, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $18.00 |
| Aug 28, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $15.00 |
| Aug 5, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $10.00 |
| Aug 5, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $14.00 |
| Aug 5, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $18.00 |
| Jun 20, 2025 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $N/A |
| May 28, 2025 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $4.00 |
| May 27, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $81.00 |
| May 27, 2025 | JMP Securities | Jason Butler | Market Outperform | Maintains | $29.00 |
| May 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $14.00 |
| May 27, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $18.00 |
| May 27, 2025 | Oppenheimer | Jay Olson | Perform | Downgrade | $N/A |
| May 9, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $30.00 |
Prothena Corporation plc (PRTA) Competitors
The following stocks are similar to Prothena based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prothena Corporation plc (PRTA) Financial Data
Prothena Corporation plc has a market capitalization of $586.78M with a P/E ratio of -2.4x. The company generates $9.68M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -99.0% quarter-over-quarter, while maintaining an operating margin of -129,576.2% and return on equity of -63.6%.
Valuation Metrics
Market Cap
$586.78M
Enterprise Value
$287.62M
P/E Ratio
-2.4x
PEG Ratio
0.0x
Price/Sales
60.6x
Growth & Margins
Revenue Growth (YoY)
-99.0%
Gross Margin
N/A
Operating Margin
-129,576.2%
Net Margin
0.0%
EPS Growth
-99.0%
Financial Health
Cash/Price Ratio
+52.4%
Current Ratio
7.7x
Debt/Equity
3.0x
ROE
-63.6%
ROA
-26.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prothena Corporation plc (PRTA) Business Model
About Prothena Corporation plc
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
The company focuses on discovering and developing innovative therapies targeting protein misfolding, particularly in neurodegenerative diseases and rare conditions. Prothena generates revenue through collaborations with major pharmaceutical companies, such as Roche and Novo Nordisk, to advance its drug candidates through clinical trials.
Additional Information
Prothena has a robust pipeline featuring several late-stage candidates, including prasinezumab for Parkinson's disease and coramitug for transthyretin amyloidosis. The company is strategically positioned in the biotechnology sector, with ongoing partnerships and a commitment to delivering transformative treatments for significant health challenges. Founded in 2012 and based in Dublin, Ireland, Prothena is at the cutting edge of neuroscience innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
163
CEO
Dr. Gene G. Kinney Ph.D.
Country
Ireland
IPO Year
2012
Website
www.prothena.comProthena Corporation plc (PRTA) Latest News & Analysis
Latest News
Prothena Announces Leadership Team Updates
10 days ago
Quick Summary
Prothena has appointed Ms. Kingston as Chief Strategy Officer and Mr. Isaacs as General Counsel and Corporate Secretary, while Mr. Malecek will depart in June.
Why It Matters
Leadership changes at Prothena may impact strategic direction and governance, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
25 days ago
Quick Summary
Analysts' price targets for Prothena (PRTA) suggest a 120.2% upside, supported by increased earnings estimates, despite mixed effectiveness of price targets.
Why It Matters
Analysts' high price targets for Prothena suggest significant potential gains, and consensus on raised earnings estimates indicates positive market sentiment, influencing stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Prothena presented clinical data updates for prasinezumab (Parkinson's) and BMS-986446 (Alzheimer's) at the AD/PD™ 2026 conference.
Why It Matters
Clinical updates on prasinezumab and BMS-986446 could influence Prothena's stock performance, impacting investor sentiment and potential market value in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Prothena received a $50 million milestone payment from Novo Nordisk for enrolling participants in the Phase 3 CLEOPATTRA trial for coramitug, targeting ATTR-CM.
Why It Matters
Prothena's $50 million milestone from Novo Nordisk signals progress in the CLEOPATTRA trial, potentially boosting investor confidence and impacting future revenue projections.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
1 month ago
Quick Summary
Prothena (PRTA) has a consensus price target indicating a potential 118.1% upside. Upward earnings estimate revisions suggest possible near-term stock growth.
Why It Matters
The 118.1% upside potential for Prothena (PRTA) suggests significant growth expectations, while positive earnings revisions indicate possible near-term stock gains.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Prothena Corporation maintains a Hold rating amid mixed phase 2 data. Key assets are in phase 3 trials, with completion expected in 2029. A partnership with BMS offers up to $1.55 billion in milestones.
Why It Matters
Prothena's mixed phase 2 data and delayed program timelines may affect stock performance, while potential BMS partnership milestones could drive future value.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PRTA Stock
What is Prothena Corporation plc's (PRTA) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Prothena Corporation plc (PRTA) has a median price target of $19.00. The highest price target is $36.00 and the lowest is $8.00.
Is PRTA stock a good investment in 2026?
According to current analyst ratings, PRTA has 3 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $10.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRTA stock?
Wall Street analysts predict PRTA stock could reach $19.00 in the next 12 months. This represents a 74.3% increase from the current price of $10.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prothena Corporation plc's business model?
The company focuses on discovering and developing innovative therapies targeting protein misfolding, particularly in neurodegenerative diseases and rare conditions. Prothena generates revenue through collaborations with major pharmaceutical companies, such as Roche and Novo Nordisk, to advance its drug candidates through clinical trials.
What is the highest forecasted price for PRTA Prothena Corporation plc?
The highest price target for PRTA is $36.00 from Yasmeen Rahimi at Piper Sandler, which represents a 230.3% increase from the current price of $10.90.
What is the lowest forecasted price for PRTA Prothena Corporation plc?
The lowest price target for PRTA is $8.00 from at , which represents a -26.6% decrease from the current price of $10.90.
What is the overall PRTA consensus from analysts for Prothena Corporation plc?
The overall analyst consensus for PRTA is neutral. Out of 20 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $19.00.
How accurate are PRTA stock price projections?
Stock price projections, including those for Prothena Corporation plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:44 AM UTC